Display options
Cite
Shepard BD, Ecelbarger CM. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Semin Nephrol. 2021;41(4):331-348doi: 10.1016/j.semnephrol.2021.06.005.
Shepard, B. D., & Ecelbarger, C. M. (2021). Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Seminars in nephrology, 41(4), 331-348. https://doi.org/10.1016/j.semnephrol.2021.06.005
Shepard, Blythe D, and Ecelbarger, Carolyn M. "Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization." Seminars in nephrology vol. 41,4 (2021): 331-348. doi: https://doi.org/10.1016/j.semnephrol.2021.06.005
Shepard BD, Ecelbarger CM. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Semin Nephrol. 2021 Jul;41(4):331-348. doi: 10.1016/j.semnephrol.2021.06.005. PMID: 34715963.
Copy Download .nbib Format: NLM
Share it on

Semin Nephrol. 2021 Jul;41(4):331-348. doi: 10.1016/j.semnephrol.2021.06.005.

Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization.

Seminars in nephrology

Blythe D Shepard, Carolyn M Ecelbarger

Affiliations

  1. Department of Human Science, Georgetown University Medical Center, Washington, DC.
  2. Department of Medicine, Georgetown University Medical Center, Washington, DC. Electronic address: [email protected].

PMID: 34715963 DOI: 10.1016/j.semnephrol.2021.06.005

Abstract

Diabetes is a worldwide epidemic that is increasing rapidly to become the seventh leading cause of death in the world. The increased incidence of this disease mirrors a similar uptick in obesity and metabolic syndrome, and, collectively, these conditions can cause deleterious effects on a number of organ systems including the renal and cardiovascular systems. Historically, treatment of type 2 diabetes has focused on decreasing hyperglycemia and glycated hemoglobin levels. However, it now is appreciated that there is more to the puzzle. Emerging evidence has indicated that newer classes of diabetes drugs, sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1-receptor agonists, improve cardiovascular and renal function, while appropriately managing hyperglycemia. In this review, we highlight the recent clinical and preclinical studies that have shed light on sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1-receptor agonists and their ability to stabilize blood glucose levels while offering whole-body protection in diabetic and nondiabetic patient populations.

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: Kidney; cardiovascular; diabetes; flozins; hyperglycemia; renal

Publication Types

Grant support